Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 7, 2026 [3]. - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that defendants made false and misleading statements regarding Inovio's CELLECTRA device manufacturing deficiencies [5]. - It is claimed that Inovio was unlikely to submit the INO-3107 Biologics License Application to the FDA by the second half of 2024 due to insufficient information [5]. - The lawsuit asserts that the overall regulatory and commercial prospects of INO-3107 were overstated, leading to material misstatements by the defendants [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, Inc. due to allegations of violations of federal securities laws related to misleading statements and inadequate disclosures regarding the company's product development and regulatory prospects [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Inovio to contact them for discussing legal options, particularly for those who purchased securities between October 10, 2023, and December 26, 2025 [1]. - There is an April 7, 2026 deadline for investors to seek the role of lead plaintiff in a federal securities class action against Inovio [2]. - The complaint alleges that Inovio and its executives made false statements regarding the manufacturing of the CELLECTRA device and the prospects of the INO-3107 Biologics License Application (BLA) [4]. Group 2: Regulatory Developments - On December 29, 2025, the FDA accepted Inovio's BLA for INO-3107 for recurrent respiratory papillomatosis but indicated that the company did not provide sufficient information for accelerated approval [5]. - Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share following the FDA's announcement [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2026, to serve as lead plaintiff, representing other class members [2]. - The lawsuit alleges that Inovio made false and misleading statements regarding the manufacturing of its CELLECTRA device and the prospects of its INO-3107 Biologics License Application (BLA) [4]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms issuing notices may lack the necessary experience and resources [3]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 7, 2026 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements since 2013 [4] Group 3: Case Allegations - The lawsuit alleges that Inovio made false and misleading statements regarding the manufacturing of its CELLECTRA device and the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024 [5] - It is claimed that Inovio lacked sufficient information to justify the eligibility of the INO-3107 BLA for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [5] - The lawsuit asserts that when the true details became known, investors suffered damages due to the misleading public statements made by the defendants [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by April 7, 2026 [2][4]. Group 1: Allegations Against Inovio Pharmaceuticals - The complaint alleges that Inovio and its executives made false and misleading statements regarding the manufacturing of the CELLECTRA device, which was deficient [4][10]. - It is claimed that Inovio is unlikely to submit the Biologics License Application (BLA) for INO-3107 to the FDA by the second half of 2024 due to insufficient information [4][10]. - The overall regulatory and commercial prospects of INO-3107 were overstated, leading to materially false and misleading public statements by the defendants [4][10]. Group 2: FDA Interaction and Stock Impact - On December 29, 2025, the FDA accepted Inovio's BLA for INO-3107 for standard review but noted inadequate information for accelerated approval [5][10]. - Following this announcement, Inovio's stock price fell by $0.56 per share, representing a 24.45% decrease, closing at $1.73 per share [6][10]. Group 3: Legal Proceedings and Investor Actions - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members [7][10]. - Faruqi & Faruqi encourages anyone with information regarding Inovio's conduct to contact the firm, including whistleblowers and former employees [8][10].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is April 7, 2026, with the lead plaintiff acting on behalf of other class members [3]. Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]. Group 3: Case Allegations - The lawsuit alleges that Inovio made false and misleading statements regarding the manufacturing of its CELLECTRA device and the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024 [5]. - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [5]. - The lawsuit asserts that when the true details became known, investors suffered damages due to the misleading public statements made by the defendants [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Inovio securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2026, to serve as lead plaintiff [2] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] Group 2: Case Allegations - The lawsuit alleges that during the Class Period, defendants made false and misleading statements regarding Inovio's CELLECTRA device manufacturing and the likelihood of submitting the INO-3107 Biologics License Application to the FDA [4] - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [4] - The lawsuit asserts that when the true details became public, investors suffered damages due to the misleading statements made by the defendants [4]

Core Viewpoint - The Gross Law Firm is notifying shareholders of Inovio Pharmaceuticals, Inc. regarding a class action lawsuit due to alleged misleading statements and deficiencies related to the company's product candidate INO-3107 [1][3]. Group 1: Allegations - The complaint alleges that during the class period from October 10, 2023, to December 26, 2025, Inovio issued materially false and misleading statements [3]. - Specific allegations include deficiencies in the manufacturing of Inovio's CELLECTRA device and the unlikelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [3]. - It is claimed that Inovio lacked sufficient information to justify the eligibility of INO-3107 for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [3]. Group 2: Class Action Details - Shareholders who purchased shares of INO during the specified class period are encouraged to register for the class action, with a deadline of April 7, 2026, to seek lead plaintiff status [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for the shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, Inc. regarding alleged violations of federal securities laws related to misleading statements about the company's product development and regulatory prospects [2][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Inovio to contact them to discuss legal options, particularly for those who purchased securities between October 10, 2023, and December 26, 2025 [1]. - There is an April 7, 2026 deadline for investors to seek the role of lead plaintiff in a federal securities class action against Inovio [2]. - The complaint alleges that Inovio and its executives made false statements regarding the manufacturing of the CELLECTRA device and the likelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [5]. Group 2: Regulatory Developments - On December 29, 2025, the FDA accepted Inovio's BLA for INO-3107 for standard review but noted that the company did not provide sufficient information for accelerated approval [6]. - Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share following the FDA's announcement [7]. - Inovio plans to request a meeting with the FDA to discuss potential pathways for pursuing accelerated approval despite the current setback [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2026, to serve as lead plaintiff [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that defendants made false and misleading statements regarding Inovio's CELLECTRA device manufacturing and the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024 [5]. - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [5]. - The lawsuit asserts that when the true details became public, investors suffered damages due to the misleading statements made by the defendants [5].